What Zura Bio Ltd does.

We are a clinical-stage biotechnology company developing novel and differentiated medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with significant unmet medical need. These diseases are often chronic, biologically complex and difficult to treat, and many patients do not achieve durable disease control with currently available therapies.

Our strategy is to identify immune-mediated diseases in which translational and clinical evidence supports the role of specific biological pathways in disease pathogenesis. We focus on targets for which human data, including biomarker findings, genetic associations and prior clinical studies, inform therapeutic rationale and development decisions. We seek to advance product candidates in therapeutic areas where there remains meaningful unmet medical need and where, if clinical benefit is demonstrated, there may be potential for commercial relevance.

1. Tibulizumab (ZB-106) , a humanized bispecific antibody engineered to bind and neutralize interleukin-17A (“IL-17A”) and B cell activating factor (“BAFF”) within a single therapeutic molecule.

Revenue and profit, by fiscal year.

More on ZURA.

• Zura Bio Ltd summary
• Zura Bio Ltd financial statements
• Zura Bio Ltd key metrics
• Zura Bio Ltd health scores and style box
• Zura Bio Ltd earnings
• Zura Bio Ltd dividends
• Zura Bio Ltd valuation
• Zura Bio Ltd ownership and insiders
• Zura Bio Ltd peers

Figures from Zura Bio Ltd's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.